← ANALYST RATINGS · TIPRANKS
Exagen (XGN): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy0 Hold0 Sell
Ratings of 5 analysts in the last 3 months12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $10.40, the highest $12.00, the lowest $9.00. The average is +34.7% from the last price of $7.72.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $9.00 → $8.00−11.1% | Hold | +3.6% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $8.50 → $8.00−5.9% | Hold | +3.6% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $8.50 → $8.00−5.9% | Hold | +3.6% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $9.00 → $8.00−11.1% | Hold | +3.6% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $9.00 → $8.00−11.1% | Hold | +3.6% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $8.50 → $7.50−11.8% | Hold | −2.8% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% | TD Cowen | $10.00 → $11.00+10.0% | Buy | +42.5% | Reiterated | 13.10.26on TipRanks 08:46 | +2.8%next day +0.4% | ↗ |
| Max Masucci★★★★★★★★★★#2606 · hits 42% · avg +8.5% | Roth MKM | $9.00 → $11.00+22.2% | Buy | +42.5% | Reiterated | 22.09.26on TipRanks 09:10 | +1.4%next day −1.5% · 5 days −3.8% | ↗ |
| Mayank Mamtani★★★★★★★★★★#2653 · hits 38% · avg +5.8% | B. Riley Securities | $12.00 | Buy | +55.4% | Reiterated | 11.09.26on TipRanks 08:55 | 0.0%next day +5.0% · 5 days +19.7% | ↗ |
| Mark Massaro★★★★★★★★★★#2635 · hits 40% · avg +5.7% | BTIG | $8.00 → $9.00+12.5% | Buy | +16.6% | Reiterated | 05.08.26on TipRanks 07:36 | +3.3%next day −0.7% · 5 days −1.3% | ↗ |
| Kyle Mikson CFA★★★★★★★★★★#2814 · hits 38% · avg +5.9% | Canaccord Genuity | $8.00 → $9.00+12.5% | Buy | +16.6% | Reiterated | 05.08.26on TipRanks 07:30 | +3.3%next day −0.7% · 5 days −1.3% | ↗ |
| William Bonello★★★★★★★★★★#152 · hits 66% · avg +35.0% | Craig-Hallum | $12.00 → $10.00−16.7% | Buy | +29.5% | Assigned | 11.03.26on TipRanks 12:35 | −4.2%next day +3.1% · 5 days −0.7% | ↗ |
| Paul Knight★★★★★★★★★★#4215 · hits 45% · avg +3.5% | KeyBanc | $15.00 → $10.00−33.3% | Buy | +29.5% | Reiterated | 11.03.26on TipRanks 06:40 | −4.2%next day +3.1% · 5 days −0.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Exagen
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 13.10.26: target $10.40 at a price of $8.25 (+26.1%); now: $10.40 at $7.72 (+34.7%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 5 | 5 | 4 | 4 | 3 |
| Buy | 2 | 1 | 1 | 3 | 4 | 5 |
| Hold | 0 | 0 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 16.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.18 (from $-0.20 to $-0.16). Last quarter: $-0.13.
Sales
Next quarter’s sales estimate — $18M (from $18M to $19M). Last quarter: $20M.
Best top-analyst consensus in the sector · Healthcare
About Exagen
- CEO: John Aballi
- Employees: 216
- 1261 Liberty Way, Vista, CA, 92081, US
- www.exagen.com
Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.
Data from the stock’s TipRanks forecast page, read 168 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗